Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125237032 | 12523703 | 2 | F | 20160430 | 20160707 | 20160704 | 20160713 | EXP | IT-009507513-1606ITA014779 | MERCK | 78.00 | YR | F | Y | 0.00000 | 20160713 | OT | IT | IT |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125237032 | 12523703 | 1 | PS | REBETOL | RIBAVIRIN | 1 | Oral | 5 DOSES UNIT, DAILY | 20903 | 5 | DF | CAPSULE | QD | ||||||
125237032 | 12523703 | 2 | SS | VIEKIRAX | OMBITASVIRPARITAPREVIRRITONAVIR | 1 | Oral | 2 DOSES UNIT, DAILY | 0 | 2 | DF | QD | |||||||
125237032 | 12523703 | 3 | SS | EXVIERA | DASABUVIR | 1 | Oral | 2 DOSES UNIT, DAILY | 0 | 2 | DF | QD |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125237032 | 12523703 | 2 | Chronic hepatitis C |
125237032 | 12523703 | 3 | Chronic hepatitis C |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
125237032 | 12523703 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125237032 | 12523703 | Fatigue | |
125237032 | 12523703 | Somnolence |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
125237032 | 12523703 | 1 | 20160420 | 0 | ||
125237032 | 12523703 | 2 | 20160420 | 0 | ||
125237032 | 12523703 | 3 | 20160420 | 0 |